Correlative microscopy with ZEISS Atlas 5 and Gemini optics paves new ways for cancer research
A new ZEISS GeminiSEM 300 system has arrived at the Ingham Institute in Sydney. The instrument, the first of its kind installed in Australia, is specifically configured and optimised for examination of cancer tissue and new nanotechnology-based probes. The field emission scanning electron microscope (FE-SEM) from ZEISS will be used to characterise tumour cells and assist with patient prognostic assessment. It does this by allowing examination of the same structure within a single section of a tissue specimen by multiple methods of microscopy and microanalysis. The new state of the art FE-SEM at the Ingham Institute provides not only excellent low-voltage imaging capability but also features the ZEISS Atlas 5 correlative microscopy solution that makes creating comprehensive multi-scale, multi-modal images possible with a sample-centric correlative environment. Efficient navigation and correlation of images is possible between various imaging modalities e.g. ZEISS light, electron, focused ion beam (FIB-SEM) or X-ray microscopes.
This approach will enable the team at the Ingham institute to look at cancer biopsies and surgical tissue in a new light gaining insight into function and structure like never before. Thanks to Atlas 5, ZEISS GeminiSEM 300 is also the first instrument in Australia to provide automated imaging of correlative array tomography sections. This functionality will allow the team to capture vast numbers of sections for reconstruction in an automated process. This ability provides the institute, pathologists and UNSW users with 3D imaging reconstruction capability and the chance to better understand cancer tissue as a whole.
Associate Professor Murray Killingsworth commented that “The recent arrival of ZEISS GeminiSEM 300 at the Ingham Institute marked a significant day in the establishment of a world-class cancer cell microscopy facility at the Institute. The instrument acquisition was made possible by the formation of a new research partnership between the Ingham Institute, New South Wales Health Pathology and the University of New South Wales Australia and the success of the new team in securing crucial funding from the Cancer Institute of NSW. ZEISS GeminiSEM 300 will allow researchers unprecedented clarity in their studies of cancer cell pathology. Correlative information can now be viewed in massive 3D images that visualize the complex interactions of cancer cells with their microenvironment and the host immune system.”
ZEISS is honoured to support this Australian first at the Ingham Institute with very special thanks to Cancer Institute NSW, New South Wales Health Pathology (NSWHP), Centre for Oncology Education & Research Translation (CONCERT) and UNSW Australia for generous support.
About the Ingham Institute
The Ingham Institute for Applied Medical Research at Liverpool Hospital conducts world-class medical research. Founded by the community for the community, our award-winning researchers are dedicated to finding better ways to improve health. The Institute’s research team are focused on exploring new medical approaches across its five research streams. These include: Cancer, Clinical Science (comprising Cardiovascular Disease, Diabetes and Infectious and Inflammatory Diseases), Population & Health Services, Injury and Rehabilitation and Mental Health. They are at the forefront of the most advanced medical breakthroughs and clinical discoveries and are committed to saving and improving lives. All of the Institute’s medical research programs have a translational focus. This means that results from the laboratory are transformed into direct health benefits in the form of new treatments and standards of care for local, national and international communities. The Ingham Institute operates as a unique partnership between the South Western Sydney Local Health District (SWSLHD), UNSW Australia and Western Sydney University. It was founded by one of Australia’s most respected philanthropists Bob Ingham AO and is further supported by Mary Fairfax AC, OBE.